Amarin Announces First Notification of U.S. Patent Allowance Based on ANCHOR Clinical Trial Results

Amarin Announces First Notification of U.S. Patent Allowance Based on ANCHOR
Clinical Trial Results

Key 12/815,569 Patent Application Related to Patient Population With Mixed

BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 23, 2013 (GLOBE NEWSWIRE) -- Amarin
Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health, announced today that the United States Patent and Trademark Office
(USPTO) has published notification of a Notice of Allowance for Amarin's U.S.
Patent Application Serial Number 12/815,569 titled "Compositions and Methods
for Lowering Triglycerides Without Raising LDL-C Levels in a Subject on
Concomitant Statin Therapy." This application includes claims intended to
protect the proposed Vascepa^® (icosapent ethyl) indication based
onAmarin'sPhase 3 ANCHOR clinical trial results. Amarin is on track to file
a Supplemental New Drug Application for the Vascepa ANCHOR indication with the
U.S. Food and Drug Administration(FDA) by the end ofFebruary 2013, and
expects an FDA action date on the application before the end of 2013.

A Notice of Allowance is issued after the USPTO makes a determination that a
patent can be granted from an application. The issued patent would have a term
that expires no earlier than in 2030. Amarin plans to list this patent in the
FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or
Orange Book, after issuance of the patent and the anticipated approval of
Vascepa in the ANCHOR indication.

The claims in thisallowed applicationcover a method of use relating to
Vascepa's ANCHOR indication. Specifically, the allowed independent claim
covers use of icosapent ethyl, or EPA, including Vascepa, in lowering
triglycerides through the daily administration of about 4 capsules, each
containing about 900 mg to about 1000 mg of EPA, regardless of EPA purity with
not more than about 3% docosahexaenoic acid.

"We are very pleased to announce this Notice of Allowance, the first from many
pending patent applications with the USPTO expected to cover our planned
ANCHOR indication for Vascepa," stated Joseph Zakrzewski, Chairman and CEO of
Amarin. "The claims cover a significant range of EPA dosage strengths
administered to patients on any statin product.This allowance is based upon
showings that important clinical results for Vascepa inAmarin'sANCHOR trial
were surprising and unexpected, key factors considered by the USPTO in
granting a patent."

This application is part of an expanding patent portfolio for Amarin with 13
patent applications now either issued or allowed with the USPTO and over 30
additional applications pending in the United States. Amarin is also pursuing
patent applications related to Vascepa in multiple jurisdictions outside the
United States.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl), Amarin's first FDA
approved product, is a patented, ultra pure omega-3 fatty acid product
comprising not less than 96% EPA. For more information about Vascepa visit For more information about Amarin visit

The Amarin Corporation plc logo is available at

Forward-looking statements

This press release contains forward-looking statements, including statements
about whether the subject patent would be issued and adequately protect
Vascepa against competition, the expiration date of the pending patent,
Amarin's plan to list the patent, when issued, in FDA's Orange Book assuming
FDA approval of the ANCHOR indication, the anticipated approval of Vascepa in
the ANCHOR indication, Amarin's plan to protect the commercial potential of
Vascepa, the future status of pending patent applications, planned regulatory
submissions and expected action dates. These forward-looking statements are
not promises or guarantees and involve substantial risks and uncertainties.
Among the factors that could cause actual results to differ materially from
those described or projected herein include the following: events that could
interfere with the issuance of a patent, or once issued, the continued
validity or enforceability of a patent; Amarin's ability generally to maintain
adequate patent protection and successfully enforce patent claims against
third parties; commercializing Vascepa without violating the intellectual
property rights of others; and uncertainties associated generally with
research and development, clinical trials clinical trial enrollment in
Amarin's REDUCE-IT trial and related regulatory submissions, action dates and
approvals. A further list and description of these risks, uncertainties and
other risks associated with an investment in Amarin can be found in Amarin's
filings with the U.S. Securities and Exchange Commission, including its most
recent Quarterly Report on Form 10-Q. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. Amarin undertakes no obligation to
update or revise the information contained in this press release, whether as a
result of new information, future events or circumstances or otherwise.

Amarin'sproduct candidates are in various stages of development and are not
available for sale or use outside of approved clinical trials. Nothing in this
press release should be construed as promoting the use of such product

CONTACT: Stephen D. Schultz
         Investor Relations and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315

company logo
Press spacebar to pause and continue. Press esc to stop.